MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)

Organon

Status and phase: Completed; Phase 3

Conditions: Hypercholesterolemia

Treatments: Drug: Comparator: atorvastatin; Drug: MK0653A, ezetimibe (+) simvastatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00092690

2004_051

0653A-051

Details and patient eligibility

About

This study is to assess the safety and efficacy of an investigational drug as compared to an approved drug to reduce specific cholesterol levels.

Full description

The duration of treatment is 6 weeks.

Enrollment: 1,902 patients

Sex: All

Ages: 18 to 79 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Elevated cholesterol

Exclusion criteria

• Unstable medical conditions or significant heart problems within 3 months prior to first study visit.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind